Skip to content
Peptidepedia

BPC-157 Research: Clinical Studies, Evidence & Scientific Review (2026)

From Peptidepedia, the trusted peptide wiki.

Research Evidence

The body of BPC-157 research consists primarily of preclinical animal studies, with very limited human clinical data. A 2025 systematic review identified 36 studies from 1993 to 2024, including 35 preclinical studies and only 1 clinical study.

Tendon Healing: Multiple rat studies demonstrated that BPC-157 improved structural, functional, and biomechanical outcomes following transection of the Achilles and quadriceps tendons. Treated animals showed improved load-to-failure, reduced inflammatory infiltrates, and enhanced tendon-to-bone healing.

Muscle Injury: In rat muscle transection and crush injury models, BPC-157 treatment improved muscle structure, function, and biomechanics, including improved load to failure, motor function indices, and reduced atrophy.

Ligament Repair: A rat medial collateral ligament (MCL) transection study found that BPC-157 reduced post-injury valgus instability and contracture while restoring biomechanical properties and motor function.

Bone Healing: In rabbit nonunion models, intramuscular BPC-157 performed comparably to autologous bone marrow or bone grafting in improving callus mineralization and bone defect resolution.

Human Data: Only one registered clinical trial (Phase I) exists, with an unknown status since 2016. The single retrospective human study included 12 patients who received intra-articular BPC-157 for chronic knee pain, of whom 7 reported symptom improvement lasting more than 6 months.

Frequently Asked Questions

Preclinical animal studies have shown no acute toxicity across multiple organ systems at various doses over 6-week periods. However, human clinical safety data are essentially nonexistent. The FDA has expressed concerns about potential immunogenicity and unknown long-term effects. Additionally, unregulated manufacturing creates contamination risks.

BPC-157 exists in a regulatory gray area. It is not FDA-approved and cannot legally be sold for human consumption. However, it is legally sold as a 'research chemical' and is not a DEA-scheduled substance, so possession is not illegal. Many online vendors and medical clinics offer BPC-157 products.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025.
  2. Sikiric P, et al. Multifunctionality and Possible Medical Application of the Pentadecapeptide BPC 157. Pharmaceuticals. 2025.
  3. Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014.
  4. Examine.com. BPC-157: Research Breakdown.
  5. U.S. Anti-Doping Agency. BPC-157: Experimental Peptide Creates Risk for Athletes.
  6. World Anti-Doping Agency. The 2024 Prohibited List International Standard.
  7. ClinicalTrials.gov. PCO-02 - Safety and Pharmacokinetics Trial.
  8. Rupa Health. BPC 157: Science-Backed Uses, Benefits, Dosage, and Safety.
  9. Drip Hydration. The Wolverine Stack: Can BPC 157 and TB 500 Accelerate Injury Recovery?
  10. Preferred Regenerative Medicine. The BPC-157, TB-500, KPV & GHK-Cu Peptide Stack Guide.
  11. Sikiric P, et al. Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy. PubMed.
  12. Sikiric P, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide, Literature and Patent Review. PubMed.
←Read the full BPC-157 guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”